Is Bioxytran, Inc. (BIXT) a Buy, Sell, or Hold?
OTC : BIXT
Bioxytran, Inc.
$0.0214 USD
$0.0 (-18.63%)
- Volume
- 31.9K
- Average Volume
- 88.81K
- Market Capitalization
- $2.12M
- P/E Ratio
- -0.81
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.09
- Year Low
- $0.02
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.09
Company Overview
OTC
David Platt
Biotechnology
Healthcare
BIXT
2
US
USD
Liquidity Metrics
-0.28
0.09
0.09
0.09
0.00
Sales & Valuation
-$
0.00
-0.55
-3.40
-0.01
Profitability
-$0.0231
-$2.12M
0.00%
0.00%
90.64%
-461.34%
P/E Metrics
-0.81
-0.01
-0.01
Analyst Price Target & Rating
2/5
0 Analysts
%
Financial Health Scores
-74.44
2/9
-$4.55M
$615.25K
$5.01M
-$2.47M
Key Metrics (TTM)
$2.92M
0.00
-1.19
0.09
90.64%
102.75%
-114.91%
-28.59%
-32956 days
Company Executives
| Name | Title |
|---|---|
| Ola Soderquist CM&AA | CFO & Treasurer |
| David Platt | Chairman, CEO, President & Secretary |
Poll Results
No votes yet today — be the first to share your view!
About Bioxytran, Inc. (OTC:BIXT) Stock
Bioxytran, Inc. is a pharmaceutical firm operating in the clinical development phase, dedicated to creating, producing, and marketing medicinal treatments for oxygen deficiency (hypoxia) in people. Its primary drug under development, BXT-25, is a small, oxygen-transporting molecule crafted from bovine hemoglobin, stabilized by a co-polymer. This compound is intended for tackling oxygen deprivation in the brain caused by strokes, as well as addressing wound hypoxia to avert tissue death and encourage recovery. Additionally, Bioxytran is advancing ProLectin-Rx, a pectin-derived polysaccharide. This substance functions by attaching to and inhibiting galectin-1, a specific galectin, to treat mild to moderate instances of Covid-19. Established in 2008, the company maintains its main office in N ... ewton, Massachusetts.
2026-08-04 07:00:00
Company's ASI-Powered Carbohydrate Design Platform, in Collaboration with University of Minnesota Department of Chemistry, Represents Paradigm Shift in Rational Drug Discovery Boston Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company pioneering innovative therapies for viral diseases and cancer metastasis, today announced the execution of a second Sponsored Research Agreement with the University of Minnesota's Department of Chemistry to support advanced biochemical research aimed at improving the understanding and development of novel polysaccharide and oligosaccharide interactions with biologically relevant targets.
Bioxytran Announces Publication of Corporate Research Report by Globe Small Cap Research
2026-07-29 07:00:00
Report discusses ProLectin-M Phase 2 clinical results, planned 408-patient registrational trial, the BXT-25 oxygen-therapeutic platform, and Bioxytran's A-SUQAR commercial distribution agreement BOSTON, MASSACHUSETTS, July 29, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT) (the "Company"), a clinical-stage biotechnology company developing therapeutics in based on carbohydrate chemistry, galectin antagonism, and oxygen transport, today announced the publication of a sponsored corporate research report by Globe Small Cap Research. The report Research Bioxytran as a multi-platform biotechnology story built around carbohydrate science, galectin antagonism, and oxygen-transport therapeutics, with active programs spanning antiviral therapy, stroke and hypoxia, and an emerging commercial bridge through the Company's A-SUQAR dietary supplement.
2026-05-29 08:03:00
Brain tissue oxygenation in early stage of stroke with BXT-25 is monitored in real time BOSTON, MASSACHUSETTS, May 29, 2026 (GLOBE NEWSWIRE) -- Bioxytran Inc. (OTCQB: BIXT), a biotechnology company developing carbohydrate-based therapeutics and oxygen therapeutics, today highlighted the publication of a new scientific book by internationally recognized physiologist and researcher Avraham Mayevsky that may provide scientific perspectives relevant to future evaluation methods for oxygen therapeutics such as BXT-25. The book “Physiological Mapping of the Cerebral Cortex in Neuropathology” (978-3-032-13018-1) by Springer, was authored independently by Dr. Mayevsky, and the book introduces the concept of “Physiological Mapping,” a unique methodology designed to monitor tissue metabolism and oxygenation in vivo and in real-time.
2026-05-29 08:03:00
Brain tissue oxygenation in early stage of stroke with BXT-25 is monitored in real time BOSTON, MASSACHUSETTS, May 29, 2026 (GLOBE NEWSWIRE) -- Bioxytran Inc. (OTCQB: BIXT), a biotechnology company developing carbohydrate-based therapeutics and oxygen therapeutics, today highlighted the publication of a new scientific book by internationally recognized physiologist and researcher Avraham Mayevsky that may provide scientific perspectives relevant to future evaluation methods for oxygen therapeutics such as BXT-25.
Frequently Asked Questions
-
What is the current Bioxytran, Inc. (BIXT) stock price?
-
Bioxytran, Inc.(OTC:BIXT) stock price is $0.0214 in the last trading session. During the trading session, BIXT stock reached the peak price of $0.0949 while $0.021 was the lowest point it dropped to. The percentage change in BIXT stock occurred in the recent session was --18.63% while the dollar amount for the price change in BIXT stock was -$0.0.
-
BIXT's industry and sector of operation?
-
The OTC listed BIXT is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BIXT?
-
Ola Soderquist CM&AA | CFO & Treasurer
David Platt | Chairman, CEO, President & Secretary
|
|
| -
How many employees does BIXT have?
-
Number of BIXT employees currently stands at 2. BIXT operates from 75 2nd Avenue, Needham, MA 02494, US.
-
Link for BIXT official website?
-
Official Website of BIXT is: https://www.bioxytraninc.com
-
How do I contact BIXT?
-
BIXT could be contacted at phone #617-454-1199 and can also be accessed through its website. BIXT operates from 75 2nd Avenue, Needham, MA 02494, US.
-
How many shares of BIXT are traded daily?
-
The average number of BIXT shares traded daily for last 3 months was 88.81K.
-
What is the market cap of BIXT currently?
-
The market value of BIXT currently stands at $2.12M with its latest stock price at $0.0214